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Background
The efficacy, safety, and tolerability of nootropic choli-
nergic agent: GALANTAMINE (with a dual mechanism
of action on the cholinergic a system) and moderate
affinity NMDA- receptor antagonist: MEMANTINE,
were assessed taking into account the profile of patients
with neurocognitive disorder: Alzheimer’s disease, from
the clinical aspects and the different classifications.
Materials and methods
The experience included 380 patients who were enrolled
in a prospective, observational, multicenter, and open-
label study to receive 16 mg/day of galantamine and
30 mg/day of memantine for 12 months of treatment of
addition.
Results
The therapeutic response was measured using the Mini
Mental State Examination (MMSE), Clinical Dementia
Rating (CDR), Alzheimer’s Disease Assessment Scale
(ADAS-GOG), Functional Activities Questionnaire
(FAQ) the Clinical Global Impression Scale (CGI) and
the UKU scale of adverse effects taking into account the
efficacy, safety and adverse events of the treatment.
Conclusions
The final results of the study showed that galantamine
with addition memantine improves cognition, beha-
vioural symptoms, and the general well-being of patients
with cognitive impairment: Alzheimer’s disease. The
incidence of adverse events was not significant and a
very good profile of tolerability and safety was observed.
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